Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
The purpose of this study is to evaluate efficacy and safety of mFOLFOX6+bevacizumab and mFOLFOX6+cetuximab for liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancer.
Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer
DRUG: Bevacizumab|DRUG: Cetuximab|DRUG: L-OHP|DRUG: l-LV|DRUG: 5-FU|DRUG: 5-FU
Progression-free survival, assessed by Independent Review Committee, assessed every 8 weeks, up to 4 years
Response rate, assessed every 8 weeks, up to 4 years
Tumor shrinkage rate at 8 week, assessed at 8 week, up to 8 weeks|Liver resection rate, assessed every 8 weeks, up to 4 years|R0 liver resection rate, pathologically confirmed R0 liver resection rate, assessed every 8 weeks, up to 4 years|Progression-free survival, assessed by investigators, assessed every 8 weeks, up to 4 years|Time to treatment-failure, assessed every 2 weeks, up to 4 years|Overall survival, assessed every 2 weeks, up to 4 years|Quality of life, assessed every 16 weeks, up to 1 year|Incidence of adverse events, assessed every 2 weeks, up to 4 years|Progression-free survival among the RAS wild type subpopulation, All the assessment is repeated for a maximum of 4 years., assessed every 8 weeks, up to 4 years
Description: The purpose of this study is to evaluate efficacy and safety of mFOLFOX6+bevacizumab and mFOLFOX6+cetuximab for liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancer.